ReviewAmerican journal of translational research2016
BRD7: a novel tumor suppressor gene in different cancers.
Review in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 58 citations in OpenAlex.
- NanoBRET Tracer Development for Class I Bromodomain Target Engagement in Live Cells.Bioconjugate chemistry · 2026Article
- NanoBRET Tracer Development for Class I Bromodomain Target Engagement in Live Cells.bioRxiv : the preprint server for biology · 2025Article
- Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- The Role of SWI/SNF Complex in Bladder Cancer.Journal of cellular and molecular medicine · 2025Review
- BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.International journal of biological sciences · 2025Article
- Tumor- and host-derived heparanase-2 (Hpa2) attenuates tumorigenicity: role of Hpa2 in macrophage polarization and BRD7 nuclear localization.Cell death & disease · 2024Article
- TRIM28 promotes tumor growth and metastasis in breast cancer by targeting the BRD7 protein for ubiquitination and degradation.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- LINC01138 expresses two novel isoforms and functions as a repressive factor in glioma cells.Heliyon · 2024Article
- Therapeutic Role of Synthetic Lethality inJournal of immunotherapy and precision oncology · 2024Review
- Article
- BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1.Cell death discovery · 2023Article
- BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma.Cell death & disease · 2023Article
- AGAP2-AS1/BRD7/c-Myc signaling axis promotes skin cutaneous melanoma progression.American journal of translational research · 2023Article
- A novel chromatin-remodeling complex variant, dcPBAF, is involved in maintaining transcription in differentiated neurons.Frontiers in cell and developmental biology · 2023Article
- LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling.Cellular and molecular life sciences : CMLS · 2022Article
- Transforming Stimulated Clone 22 (TSC-22) Interacts Directly with Bromodomain-Containing Protein 7 (BRD7) to Enhance the Inhibition of Extracellular Signal-Regulate Kinase (ERK) Pathway in Ovarian Cancer.Development & reproduction · 2022Article
- Theoretical exploration of the binding selectivity of inhibitors to BRD7 and BRD9 with multiple short molecular dynamics simulations.RSC advances · 2022Article
- Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana.Retrovirology · 2022Article
- Is BRD7 associated with spermatogenesis impairment and male infertility in humans? A case-control study in a Han Chinese population.Basic and clinical andrology · 2021Article
- Long noncoding RNA HAR1A regulates oral cancer progression through the alpha-kinase 1, bromodomain 7, and myosin IIA axis.Journal of molecular medicine (Berlin, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRD7 (bromodomain 7), also known as celtix-1, was first identified in nasopharyngeal carcinoma (NPC) cells in 2000. BRD7 is a crucial component of both functional p53 and BRCA1 (breast cancer 1, early onset) pathways. Recently, the BRD7 tumor suppressor status has been fully established. Previous studies demonstrated that BRD7 was downregulated in human breast cancer and the downregulation often associates with tumor progression. The expression of BRD7 was downregulated in various cancers, including breast cancer, NPC, gastric cancer, colorectal carcinoma, ovarian cancer, and prostate cancer. Moreover, BRD7 inhibited cancer cell growth and metastasis and promote apoptosis in vitro and in vivo via downregulating AKT pathway. In addition, BRD7 may regulate many signaling pathways including ras-raf-MEK-ERK and RB/E2F. In this review, we provide an overview of current knowledge concerning the role of BRD7 in tumor development and progression. To our knowledge, this is the first review about the role of this novel tumor suppressor gene BRD7in tumor development and progression.
Indexed as
Identifiers
27158366PMC4846923W2405648137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.